Neu­ro­crine flesh­es out its PhI­II case for val­be­nazine; Avro­bio adds to gene ther­a­py pipeline

→ Neu­ro­crine has al­ready post­ed the key late-stage da­ta that it took to the FDA in build­ing a case for In­grez­za (val­be­nazine) as a new ther­a­py for tar­dive dysk­i­ne­sia. But now it’s pub­lished the full set of da­ta in its fa­vor, in­clud­ing a note that its drug scored for 40% of the pa­tients in the drug arm who reg­is­tered at least a 50% im­prove­ment in AIMS dysk­i­ne­sia score, com­pared to 8.7% of those on place­bo. Neu­ro­crine is fac­ing a head-to-head fight with a new drug from Te­va, and a num­ber of an­a­lysts think the small­er biotech has a clear shot at dom­i­nat­ing the sec­tor. The PDU­FA date for the break­through ther­a­py is April 11.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER